This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read GT Biopharma’s 8K filing here.
About GT Biopharma
GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.
See Also
- Five stocks we like better than GT Biopharma
- Energy and Oil Stocks Explained
- D-Wave: Recent Updates Propel Shares Off 2025 Lows
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Health-Tech Revival: 3 Stocks Set for a Big 2025 Rebound
- What is the Dow Jones Industrial Average (DJIA)?
- How the $500 Billion Stargate Investment Can Boost These Stocks
